Norris Medicines achieved a significant financial turnaround in the quarter ended March 2026, reporting a standalone net profit of ₹0.05 crore compared to a net loss of ₹0.23 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this represents a 77% improvement in the company's quarterly performance. The company's operating profit margin (OPM) improved to 21.28% in Q4 FY26 from 2.57% in Q4 FY25, demonstrating enhanced operational efficiency.
Despite the profitability improvement, sales declined 48.16% to ₹1.41 crore in Q4 FY26 compared to ₹2.72 crore in Q4 FY25, as reported by Business Standard. The company's profit before depreciation, tax and interest (PBDT) turned positive at ₹0.17 crore in the quarter, marking a significant improvement from the negative ₹0.03 crore recorded in the previous year's corresponding quarter.
For the full financial year ended March 2026, Norris Medicines reported a net loss of ₹0.28 crore compared to a net loss of ₹1.24 crore in the previous year, representing a 76% improvement in annual performance. According to Business Standard, sales for the full year increased 39.69% to ₹8.13 crore from ₹5.82 crore in the previous year, indicating strong revenue growth despite quarterly challenges.
The company's profit before tax (PBT) turned positive at ₹0.05 crore in Q4 FY26 compared to a loss of ₹0.17 crore in Q4 FY25, as reported by Business Standard. For the full year, PBT improved to ₹0.21 crore from a loss of ₹0.64 crore in the previous year, demonstrating consistent improvement in the company's bottom-line performance across both quarterly and annual periods.
